Developing new technologies to create inhibitors for carbohydrate-binding proteins
Technology for Directed Evolution of Glycoaptamers
['FUNDING_R01'] · BRANDEIS UNIVERSITY · NIH-11099100
This study is working on new tools that can help find ways to block certain proteins that are important in diseases like cancer, diabetes, and heart issues, using special RNA molecules to better target these proteins and improve treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRANDEIS UNIVERSITY (nih funded) |
| Locations | 1 site (WALTHAM, UNITED STATES) |
| Trial ID | NIH-11099100 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative technologies to quickly discover inhibitors that target carbohydrate-binding proteins (CBPs), which play a crucial role in various biological processes such as immune response, cancer progression, and chronic diseases like diabetes and atherosclerosis. The approach involves developing specialized RNA-based molecules that can selectively bind to these proteins, disrupting their interactions with carbohydrates. By enhancing the binding affinity and specificity of these inhibitors, the research aims to provide effective tools for studying and potentially treating diseases linked to CBP functions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions such as atherosclerosis, diabetes, autoimmune diseases, or cancers where carbohydrate-binding proteins play a significant role.
Not a fit: Patients with conditions unrelated to carbohydrate-binding protein interactions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients suffering from diseases related to carbohydrate-binding protein interactions.
How similar studies have performed: Other research has shown promise in targeting carbohydrate-binding proteins, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
WALTHAM, UNITED STATES
- BRANDEIS UNIVERSITY — WALTHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRAUSS, ISAAC JONATHAN — BRANDEIS UNIVERSITY
- Study coordinator: KRAUSS, ISAAC JONATHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease, Cancers